Skip to main content

    The Ocular Hypertension Treatment Study: What's New in Genetics

    Glaucoma Subspecialty Day 2022
    Glaucoma, Open-Angle Glaucoma

    In this presentation from Glaucoma Subspecialty Day 2022, Dr. John Fingert discusses glaucoma genetics and the Ocular Hypertension Treatment Study (OHTS), which examined whether treating ocular hypertension prevents or delays the onset of primary open-angle glaucoma (POAG). Most cases of glaucoma are caused by the combined actions of hundreds of risk factor genes. Genome-wide association studies have identified more than 127 of these risk factors to date. Dr. Fingert and colleagues investigated the role of these known 127 risk factors in the OHTS cohort, focusing on which genes are associated with POAG and their degree of influence on risk. They also performed a genome-wide association study of the OHTS cohort to look for new genetic risk factors.